SCHEMBL1865526

SCHEMBL1865526

CCCCCC(=O)Oc1ccccc1CC.[NaH]

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.59
MEN1 O00255 1/20 0.59
RECQL P46063 1/20 0.59
KMT2A Q03164 1/20 0.59
POLM Q9NP87 2/20 0.53
POLK Q9UBT6 2/20 0.53
POLL Q9UGP5 2/20 0.53
POLH Q9Y253 2/20 0.53
THRA P10827 1/20 0.50
THRB P10828 1/20 0.50
ALOX15 P16050 1/20 0.50
PPARG P37231 2/20 0.47
PPARA Q07869 1/20 0.46
AKR1C3 P42330 1/20 0.45
AKR1C2 P52895 1/20 0.45
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
TOP2A P11388 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9275434 0.98 KDM4E (0.60) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL28008265 0.97 KDM4E (0.59) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL28371003 0.97 KDM4E (0.59) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL27761606 0.97 KDM4E (0.59) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL28210406 0.97 KDM4E (0.59) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL28575933 0.97 KDM4E (0.59) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL28366897 0.97 KDM4E (0.59) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL31396225 0.97 KDM4E (0.59) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL3505902 0.93 KDM4E (0.67) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL14359917 0.92 KDM4E (0.55) KDM4EMEN1RECQLKMT2APOLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302487-A1 COMPOSITE REVOLYMER LIMITED (GB) 2012-11-29 US claimed
EP-2494024-A1 COMPOSITE Revolymer Limited (GB) 2012-09-05 EP claimed
WO-2011051681-A1 COMPOSITE REVOLYMER LIMITED (GB) 2011-05-05 WO claimed
US-20140171327-A1 NOVEL COMPOSITE REVOLYMER (U.K.) LIMITED (GB) 2014-06-19 US disclosed
EP-2697355-A1 PARTICLES WITH HYDROXYL VINYLIC COPOLYMER COATING SENSITIVE TO IONIC STRENGTH Revolymer Limited (GB) 2014-02-19 EP disclosed
US-20120302487-A1 COMPOSITE REVOLYMER LIMITED (GB) 2012-11-29 US disclosed
WO-2012140442-A1 PARTICLES WITH HYDROXYL VINYLIC COPOLYMER COATING SENSITIVE TO IONIC STRENGTH REVOLYMER LIMITED (GB) 2012-10-18 WO disclosed
EP-2494024-A1 COMPOSITE Revolymer Limited (GB) 2012-09-05 EP disclosed
WO-2011051681-A1 COMPOSITE REVOLYMER LIMITED (GB) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171327-A1 NOVEL COMPOSITE PUF60, C5, VCL KDM4E 291/4885MEN1 3035/4885RECQL 4528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.